Celularity Inc. (NASDAQ:CELU – Get Free Report) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 680,100 shares, an increase of 6.7% from the May 31st total of 637,600 shares. Based on an average daily volume of 35,100 shares, the days-to-cover ratio is currently 19.4 days. Currently, 6.4% of the shares of the company are short sold.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Celularity stock. Keynote Financial Services LLC bought a new position in Celularity Inc. (NASDAQ:CELU – Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 15,566 shares of the company’s stock, valued at approximately $81,000. Keynote Financial Services LLC owned 0.08% of Celularity as of its most recent filing with the Securities and Exchange Commission. 19.02% of the stock is currently owned by institutional investors and hedge funds.
Celularity Trading Down 2.7 %
Shares of CELU opened at $3.11 on Wednesday. Celularity has a fifty-two week low of $1.59 and a fifty-two week high of $7.97. The firm has a 50-day simple moving average of $3.14 and a 200-day simple moving average of $3.63.
Celularity Company Profile
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.
Recommended Stories
- Five stocks we like better than Celularity
- Are Penny Stocks a Good Fit for Your Portfolio?
- Does BJ’s Wholesale Club Stock Have More Room to Grow?
- Investing In Preferred Stock vs. Common Stock
- Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- RXO Shares Surge Following New Acquisition Deal
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.
